These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 14006163)

  • 1. [Contributions to the diagnosis of blood coagulation disorders and on the supervision of anticoagulant therapy with the aid of hirudin].
    WENZEL G
    Dtsch Gesundheitsw; 1961 Nov; 16():2193-7. PubMed ID: 14006163
    [No Abstract]   [Full Text] [Related]  

  • 2. [The use of prothrombin determination with hirudin in the supervision of treatment with dicoumarol derivatives].
    MARKWARDT F; WENZEL G
    Blut; 1961 Apr; 7():37-42. PubMed ID: 13766979
    [No Abstract]   [Full Text] [Related]  

  • 3. [The hirudin test, a micromethod for control of the prothrombin level in anticoagulant therapy].
    SCHMUTZLER R; MARKWARDT F
    Klin Wochenschr; 1962 Aug; 40():796-8. PubMed ID: 13908867
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of hirudin in clinical coagulation laboratories].
    Walsmann P; Vogel G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1970; 94(2):143-52. PubMed ID: 4098769
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful renal transplantation in a patient with heterozygous prothrombin gene, factor V Leiden mutation and heparin-induced thrombocytopenia using r-hirudin as anticoagulant.
    John U; Kentouche K; Nowak G; Schubert J; Misselwitz J
    Pediatr Transplant; 2006 Feb; 10(1):114-8. PubMed ID: 16499600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biological activity of pharmacological properties of the anticoagulant complex (hirudin, plasma kallikrein inhibitor, prostaglandin) from the leech Hirudo medicinalis].
    Nikonov GI; Titova EA; Seleznev KG
    Biull Eksp Biol Med; 1999 Dec; 128(12):673-6. PubMed ID: 10650471
    [No Abstract]   [Full Text] [Related]  

  • 7. [Animal experimental tests of the prothrombin synthesis inhibition effect of coumarin derivatives].
    Markwardt F; Haustein KO
    Acta Biol Med Ger; 1966; 17(3):318-26. PubMed ID: 5987646
    [No Abstract]   [Full Text] [Related]  

  • 8. Hirudin versus heparin for use in whole blood in vitro biocompatibility models.
    Bexborn F; Engberg AE; Sandholm K; Mollnes TE; Hong J; Nilsson Ekdahl K
    J Biomed Mater Res A; 2009 Jun; 89(4):951-9. PubMed ID: 18470919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experimental study on the effect of hirudin on the factors of blood coagulation].
    PAOLO C; LINO S
    Riforma Med; 1952 Mar; 66(11):293-5. PubMed ID: 14949892
    [No Abstract]   [Full Text] [Related]  

  • 10. Investigation on recombinant hirudin via oral route.
    Cen X; Ni J; Tan T; Liu X; Li C; Chen J; Huang Y; Zhu S; Bi Q
    Peptides; 2006 Apr; 27(4):836-40. PubMed ID: 16469415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombelastographic studies with a twenty-four-hour schedule for subcutaneous heparin. A comparison of its efficiency with prothrombin-depressing agents.
    ELIOT RS; VON KAULLA KN; BLOUNT SG
    Circulation; 1961 Nov; 24():1206-14. PubMed ID: 13889849
    [No Abstract]   [Full Text] [Related]  

  • 12. A functional clotting assay to monitor the hirudin dosage.
    Zakir RM; Hoffman W; Bhatt BA; Spillert CR
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):119-23. PubMed ID: 17287627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The direct thrombin inhibitor hirudin.
    Greinacher A; Warkentin TE
    Thromb Haemost; 2008 May; 99(5):819-29. PubMed ID: 18449411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of overall coagulabity during coumar in treatment with reference to the Quick test.
    VERSTRAETE M; VERMYLEN C; VANDENBROUCKE J
    Acta Med Scand; 1960 Jun; 167():127-38. PubMed ID: 13841924
    [No Abstract]   [Full Text] [Related]  

  • 15. [Quantitative determination of prothrombin by titration with hirudin].
    MARKWARDT F
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1958; 232(3):487-98. PubMed ID: 13552727
    [No Abstract]   [Full Text] [Related]  

  • 16. Some observations on the coagulation defect during treatment with the anticoagulant sintrom.
    VERMEULEN HJ; TEN BOKKEL HUININK S; RADHAKISHUN KS
    Thromb Diath Haemorrh; 1959 Jan; 3(1):92-7. PubMed ID: 13647517
    [No Abstract]   [Full Text] [Related]  

  • 17. Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.
    Sucker C; Zotz RB; Görlinger K; Hartmann M
    Acta Anaesthesiol Scand; 2008 Mar; 52(3):358-62. PubMed ID: 18205897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
    Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
    Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complex pattern of response to coumarin drug therapy. The inadequacy of the prothrombin test as a guide to hypocoagulability.
    GOLLUB S; ULIN AW; LIKOFF W
    Am Heart J; 1962 May; 63():591-9. PubMed ID: 13899970
    [No Abstract]   [Full Text] [Related]  

  • 20. [The cephalin time in the supervision of anticoagulant therapy by derivatives of coumarin].
    d' Auteuil P; Savard Y
    Laval Med; 1966 Jun; 37(6):664-9. PubMed ID: 5937267
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.